keyword
MENU ▼
Read by QxMD icon Read
search

adjuvant treatment breast cancer

keyword
https://www.readbyqxmd.com/read/28334423/are-there-patients-with-t1-to-t2-lymph-node-negative-breast-cancer-who-are-high-risk-for-locoregional-disease-recurrence
#1
Anita Mamtani, Sujata Patil, Michelle M Stempel, Monica Morrow
BACKGROUND: Indications for postmastectomy radiotherapy (PMRT) in patients with T1 to T2, lymph node-negative (N0) breast cancer with "high-risk" features are controversial. The European Organization for Research and Treatment of Cancer (EORTC) 22922 and National Cancer Institute of Canada Clinical Trials Group MA20 trials reporting improved 10-year disease-free survival with lymph node irradiation included patients with high-risk N0 disease, but, to the authors' knowledge, benefits in patients receiving modern systemic therapy are uncertain...
March 23, 2017: Cancer
https://www.readbyqxmd.com/read/28332254/information-needs-and-decision-making-preferences-of-older-women-offered-a-choice-between-surgery-and-primary-endocrine-therapy-for-early-breast-cancer
#2
Maria Burton, Karen Kilner, Lynda Wyld, Kate Joanna Lifford, Frances Gordon, Annabel Allison, Malcolm Reed, Karen Anna Collins
OBJECTIVES: To establish older women's (≥75 years) information preferences regarding two breast cancer treatment options: surgery plus adjuvant endocrine therapy versus primary endocrine therapy (PET). To quantify women's preferences for the mode of information presentation and decision making (DM) style. METHODS: This was a UK multi-centre survey of women, ≥75 years, who had been offered a choice between PET and surgery at diagnosis of breast cancer. A questionnaire was developed including two validated scales of decision regret and DM preferences...
March 23, 2017: Psycho-oncology
https://www.readbyqxmd.com/read/28332035/opportunistic-biopsy-of-internal-mammary-lymph-nodes-during-immediate-breast-reconstruction-after-mastectomy-for-breast-malignancies
#3
Ki Yong Hong, Han-Byoel Lee, Sangjun Yim, Jongho Lee, Tae-Yong Kim, Wonshik Han, Ung Sik Jin
BACKGROUND: This study was designed to explore the clinicopathological factors associated with internal mammary lymph node (IMN) metastasis in radiologically IMN-negative breast malignancies and to discuss the clinical value of opportunistic biopsy during immediate breast reconstruction using free flaps, where the internal mammary vessels are the recipient. METHODS: We retrospectively reviewed patients who received curative total mastectomy for breast malignancy followed by immediate reconstruction using transverse rectus abdominis myocutaneous (TRAM) free flap...
March 22, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28331237/restricted-axillary-staging-in-clinically-and-sonographically-node-negative-early-invasive-breast-cancer-c-it1-2-in-the-context-of-breast-conserving-therapy-first-results-following-commencement-of-the-intergroup-sentinel-mamma-insema-trial
#4
T Reimer, A Stachs, V Nekljudova, S Loibl, S Hartmann, K Wolter, G Hildebrandt, B Gerber
Axillary lymph node status remains an important prognostic factor in early breast cancer. It is regarded as an indicator for (neo)adjuvant systemic treatment and postoperative radiotherapy of the regional lymphatics. Commenced in September 2015, the INSEMA trial is investigating whether operative determination of nodal status as part of breast conserving therapy (BCT) for early stage breast cancer (c/iT1-2 c/iN0) can be avoided without reducing oncological safety. After inclusion of 1001 patients there was general acceptance of the complex study design by patients and study doctors so that recruitment for the first randomisation (axillary sentinel lymph node biopsy [SLNB]: yes or no) achieved predicted case numbers...
February 2017: Geburtshilfe und Frauenheilkunde
https://www.readbyqxmd.com/read/28330704/an-update-on-non-extremity-soft-tissue-sarcomas
#5
S J Ford, L M Almond, A Gronchi
The management of soft tissue sarcoma is challenging and varied. Centralisation of management in high volume specialist centres has revolutionised outcomes. Surgery remains the mainstay of treatment and is currently the only potentially curative therapy. Retroperitoneal soft tissue sarcoma presents a particular challenge to the surgical oncologist and the concept of extended resection to include surrounding expendable organs taken en bloc with the tumour has now largely been adopted. The use of neoadjuvant and adjuvant therapies for retroperitoneal soft tissue sarcoma is still to be established, although they are employed on a case-specific basis...
March 19, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28325109/feasibility-and-effects-of-a-combined-adjuvant-high-intensity-interval-strength-training-in-breast-cancer-patients-a-single-center-pilot-study
#6
Sebastian Viktor Waldemar Schulz, Roman Laszlo, Stephanie Otto, Dmytro Prokopchuk, Uwe Schumann, Florian Ebner, Jens Huober, Jürgen Michael Steinacker
PURPOSE: To evaluate feasibility of an exercise intervention consisting of high-intensity interval endurance and strength training in breast cancer patients. METHODS: Twenty-six women with nonmetastatic breast cancer were consecutively assigned to the exercise intervention- (n= 15, mean age 51.9 ± 9.8 years) and the control group (n = 11, mean age 56.9 ± 7.0 years). Cardiopulmonary exercise testing that included lactate sampling, one-repetition maximum tests and a HADS-D questionnaire were used to monitor patients both before and after a supervised six weeks period of either combined high-intensity interval endurance and strength training (intervention group, twice a week) or leisure training (control group)...
March 21, 2017: Disability and Rehabilitation
https://www.readbyqxmd.com/read/28323842/the-treatment-outcomes-and-the-use-of-adjuvant-therapies-in-breast-cancer-patients-with-severe-co-morbidities
#7
Jaihong Han, Han-Byoel Lee, Eun-Shin Lee, Young Joon Kang, Yumi Kim, Jihye Choi, Jiyoung Rhu, Hee-Chul Shin, Wonshik Han, Dong-Young Noh, Hyeong-Gon Moon
PURPOSE: Studies have suggested a potential role of patient's co-morbidity in determining the survival outcomes of breast cancer. In this study, we examined the long-term oncologic outcomes in breast cancer patients who underwent curative surgery according to their pre-existing comorbid conditions and analyzed the association between the co-morbidity and the use of adjuvant therapies. METHODS: The medical records of 2,501 patients who underwent surgery for primary breast cancer from June 2006 to June 2010 were reviewed retrospectively...
2017: PloS One
https://www.readbyqxmd.com/read/28320428/a-topology-based-method-to-mitigate-the-dosimetric-uncertainty-caused-by-the-positional-variation-of-the-boost-volume-in-breast-conservative-radiotherapy
#8
Peng-Yi Lee, Chih-Yuan Lin, Shang-Wen Chen, Chun-Ru Chien, Chun-Nan Chu, Hsiu-Ting Hsu, Ji-An Liang, Ying-Jun Lin, An-Cheng Shiau
BACKGROUND: To improve local control rate in patients with breast cancer receiving adjuvant radiotherapy after breast conservative surgery, additional boost dose to the tumor bed could be delivered simultaneously via the simultaneous integrated boost (SIB) modulated technique. However, the position of tumor bed kept changing during the treatment course as the treatment position was aligned to bony anatomy. This study aimed to analyze the positional uncertainties between bony anatomy and tumor bed, and a topology-based approach was derived to stratify patients with high variation in tumor bed localization...
March 20, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28319725/antiestrogen-use-in-breast-cancer-patients-reduces-the-risk-of-subsequent-lung-cancer-a-population-based-study
#9
Sung-Chao Chu, Chia-Jung Hsieh, Tso-Fu Wang, Mun-Kun Hong, Tang-Yuan Chu
BACKGROUND: There is accumulating epidemiological and preclinical evidence that estrogen might be a driver of lung cancer. Breast cancer survivors can offer a unique patient cohort to examine the effect of antiestrogen therapy on lung cancer carcinogenesis because many of these women would have received long-term selective estrogen receptor modulators (SERMs) and/or aromatase inhibitors (AIs) as adjuvant treatment. Our hypothesis is that estrogens play a role in lung cancer development, and that antiestrogen therapy would affect the incidence of subsequent lung cancer among breast cancer survivors...
March 17, 2017: Cancer Epidemiology
https://www.readbyqxmd.com/read/28319455/joint-model-imputation-to-estimate-the-treatment-effect-on-long-term-survival-using-auxiliary-events
#10
Audrey Mauguen, Stefan Michiels, Virginie Rondeau
Clinical trial duration may be a concern in clinical research, especially in cancer trials where the endpoint is overall survival. A surrogate endpoint can be used as an auxiliary variable to analyze the treatment effect earlier. At an early time point, the high number of censored observations can be compensated by the imputation of the unobserved deaths times. We propose to use predictions of the risk of death from a joint model for a recurrent event and a terminal event, which account for disease relapse information...
February 16, 2017: Journal of Biopharmaceutical Statistics
https://www.readbyqxmd.com/read/28319069/the-branched-chain-amino-acid-transaminase-1-sustains-growth-of-antiestrogen-resistant-and-er%C3%AE-negative-breast-cancer
#11
V Thewes, R Simon, M Hlevnjak, M Schlotter, P Schroeter, K Schmidt, Y Wu, T Anzeneder, W Wang, P Windisch, M Kirchgäßner, N Melling, N Kneisel, R Büttner, U Deuschle, H P Sinn, A Schneeweiss, S Heck, S Kaulfuss, H Hess-Stumpp, J G Okun, G Sauter, A E Lykkesfeldt, M Zapatka, B Radlwimmer, P Lichter, M Tönjes
Antiestrogen-resistant and triple-negative breast tumors pose a serious clinical challenge because of limited treatment options. We assessed global gene expression changes in antiestrogen-sensitive compared with antiestrogen-resistant (two tamoxifen resistant and two fulvestrant resistant) MCF-7 breast cancer cell lines. The branched-chain amino acid transaminase 1 (BCAT1), which catalyzes the first step in the breakdown of branched-chain amino acids, was among the most upregulated transcripts in antiestrogen-resistant cells...
March 20, 2017: Oncogene
https://www.readbyqxmd.com/read/28315066/failure-patterns-according-to-molecular-subtype-in-patients-with-invasive-breast-cancer-following-postoperative-adjuvant-radiotherapy-long-term-outcomes-in-contemporary-clinical-practice
#12
Yu Jin Lim, Sea-Won Lee, Noorie Choi, Jeanny Kwon, Keun-Yong Eom, Eunyoung Kang, Eun-Kyu Kim, Sung-Won Kim, Jee Hyun Kim, Yu Jung Kim, Se Hyun Kim, So Yeon Park, Jae-Sung Kim, In Ah Kim
PURPOSE: Although gene expression profiling provides critical information, knowledge remains limited regarding the differential effects of molecular subtype on clinical course. This study evaluated the impact of molecular status on long-term patterns of failure in patients with non-metastatic breast cancer. METHODS: We analyzed data from 1181 individuals with invasive breast cancer undergoing surgery plus PORT from 2003 to 2011. Molecular subtypes were defined as luminal A (LA), luminal B (LB)-HER2(-), LB-HER2(+), HER2, and triple-negative (TN) based on the 2013 St...
March 17, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28314836/safe-heart-rationale-and-design-of-a-pilot-study-investigating-cardiac-safety-of-her2-targeted-therapy-in-patients-with-her2-positive-breast-cancer-and-reduced-left-ventricular-function
#13
Filipa Lynce, Ana Barac, Ming T Tan, Federico M Asch, Karen L Smith, Chau Dang, Claudine Isaacs, Sandra M Swain
BACKGROUND: Human epidermal growth receptor 2 (HER2) targeted therapies have survival benefit in adjuvant and metastatic HER2 positive breast cancer but are associated with cardiac dysfunction. Current U.S. Food and Drug Administration recommendations limit the use of HER2 targeted agents to patients with normal left ventricular (LV) systolic function. METHODS: The objective of the SAFE-HEaRt study is to evaluate the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and mildly reduced left ventricular ejection fraction (LVEF) with optimized cardiac therapy...
March 17, 2017: Oncologist
https://www.readbyqxmd.com/read/28293119/intensity-modulated-radiation-therapy-for-breast-cancer-current-perspectives
#14
REVIEW
Milly Buwenge, Silvia Cammelli, Ilario Ammendolia, Giorgio Tolento, Alice Zamagni, Alessandra Arcelli, Gabriella Macchia, Francesco Deodato, Savino Cilla, Alessio G Morganti
BACKGROUND: Owing to highly conformed dose distribution, intensity modulated radiation therapy (IMRT) has the potential to improve treatment results of radiotherapy (RT). Postoperative RT is a standard adjuvant treatment in conservative treatment of breast cancer (BC). The aim of this review is to analyze available evidence from randomized controlled trials (RCTs) on IMRT in BC, particularly in terms of reduction of side effects. METHODS: A literature search of the bibliographic database PubMed, from January 1990 through November 2016, was performed...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28293118/cyp2d6-polymorphisms-may-predict-occurrence-of-adverse-effects-to-tamoxifen-a-preliminary-retrospective-study
#15
Ishani Wickramage, Kamani Hemamala Tennekoon, Merenchi Arachchige Yasantha Ariyaratne, Asanka Sudeshini Hewage, Tharmini Sundralingam
INTRODUCTION AND AIMS: Tamoxifen is an adjuvant drug effective in treating hormone receptor - positive breast cancer. However, 30%-50% of patients relapse and many develop adverse effects, such as hot flashes and fatty liver. Allelic variations altering the activity of cytochrome P450-2D6 enzyme affect response to tamoxifen by modulating metabolism of tamoxifen into its pharmacologically active metabolite endoxifen. Although association between CYP2D6 polymorphisms and recurrence of breast cancer in patients on tamoxifen had been reported, little evidence exists on association between these polymorphisms and adverse effects to tamoxifen...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28291814/are-life-saving-anticancer-drugs-reaching-all-patients-patterns-and-discrepancies-of-trastuzumab-use-in-the-european-union-and-the-usa
#16
Felipe Ades, Christelle Senterre, Dimitrios Zardavas, Evandro de Azambuja, Razvan Popescu, Martine Piccart
BACKGROUND: The development of trastuzumab is considered to be one of the greatest improvements in breast cancer treatment in recent years. This study aims to evaluate changes in the uptake of trastuzumab over the last 12 years and to determine whether its use is proportional to patient needs in the European Union and the USA. METHODS: Using national registry data, the number of new cases of HER2-positive breast cancer patients per year was estimated. The number of likely trastuzumab treatments per year was estimated using trastuzumab procurement data for each country...
2017: PloS One
https://www.readbyqxmd.com/read/28291382/cost-implications-of-an-evidence-based-approach-to-radiation-treatment-after-lumpectomy-for-early-stage-breast-cancer
#17
Rachel A Greenup, Rachel C Blitzblau, Kevin L Houck, Julie Ann Sosa, Janet Horton, Jeffrey M Peppercorn, Alphonse G Taghian, Barbara L Smith, E Shelley Hwang
INTRODUCTION: Breast cancer treatment costs are rising, and identification of high-value oncology treatment strategies is increasingly needed. We sought to determine the potential cost savings associated with an evidence-based radiation treatment (RT) approach among women with early-stage breast cancer treated in the United States. PATIENTS AND METHODS: Using the National Cancer Database, we identified women with T1-T2 N0 invasive breast cancers treated with lumpectomy during 2011...
March 14, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28288389/ovarian-ablation-for-premenopausal-breast-cancer-a-review-of-treatment-considerations-and-the-impact-of-premature-menopause
#18
REVIEW
Melica Nourmoussavi, Gary Pansegrau, Jason Popesku, Geoffrey L Hammond, Janice S Kwon, Mark S Carey
Historically, ovarian ablation (OA) was used as therapy for women with recurrent hormone-receptor-positive (HRP) premenopausal breast cancer. With the publication of the SOFT (Suppression of Ovarian Function Trial) and TEXT (Tamoxifen and Exemestane Trial) randomized trials, there is considerable interest in OA as an adjuvant treatment, either in combination with tamoxifen or an aromatase inhibitor (AI). Thus, we have reviewed current guidelines and key studies on this important topic and have highlighted the relevant biological and pharmacological aspects of the various endocrine therapies...
February 22, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28286614/is-there-any-concordance-between-of-ihc-with-fish-in-her2-positive-breast-cancer-patients
#19
Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi, Alireza Janbakhsh
Background: In developed or developing countries, the most common cancer in women is breast cancer with a pick in 40-50 years in Asia. Herein, we compared the association between IHC with FISH in HER2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall survival (OS). Subjects and Methods: Immunohistochemical (IHC) analysis of hormone receptors and HER2 was performed in 133 patients with breast cancer between 2003 and 2014. Patients were selected for Herceptin adjuvant treatment, according to IHC 3+ or FISH+...
January 1, 2017: International Journal of Hematology-oncology and Stem Cell Research
https://www.readbyqxmd.com/read/28285537/milestone-clinical-trials-of-the-national-surgical-adjuvant-breast-and-bowel-project-nsabp
#20
REVIEW
Priya Rastogi, D Lawrence Wickerham, Charles E Geyer, Eleftherios P Mamounas, Thomas B Julian, Norman Wolmark
The National Surgical Adjuvant Breast and Bowel Project (NSABP) has made significant contributions in reducing the extent of breast surgery and in improving outcomes of patients with early-stage breast cancer through the conduct of large randomized clinical trials evaluating local and systemic therapy. In 2014, the NSABP merged with two other US National Cancer Institute-funded cooperative groups, the Radiation Therapy Oncology Group (RTOG) and the Gynecologic Oncology Group (GOG), to form NRG Oncology. The combined organization has 218 member institutions with more than 600 affiliate centers located throughout the United States, Canada, Puerto Rico, and other international sites...
February 2017: Chinese Clinical Oncology
keyword
keyword
116441
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"